Shares of BioSante ($BPAX) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a trial that recruited 30 patients. Story
Shares of BioSante ($BPAX) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a trial that recruited 30 patients. Story